Psoriasis Drugs Market Trends, Business Strategies, Regional Outlook and Forecast Report 2030

From 100 million in 2016, the global psoriasis prevalence surged to 125 million cases in 2020, as per the National Psoriasis Foundation. In the U.S. alone, 8 million suffer from this common disease, which is caused by strep throat and skin infections, cold, dry conditions, cuts, scrapes, bug bites, severe sunburn, stress, first- and second-hand smoke, family history, and heavy alcohol consumption. Further, almost 30% of the people suffering from this condition develop psoriatic arthritis, wherein joint stiffness, swelling, and pain occur.

As psoriatic arthritis can itself be disabling, especially if it transforms into arthritis mutilans, the focus on managing psoriasis has increased in recent years. As per P&S Intelligence, due to this reason, the psoriasis drugs market value will witness a robust 14.0% CAGR between 2021 and 2030, reaching $53,210.6 million by 2030 from $14,504.0 million in 2020. Moreover, the geriatric population is increasing, which is driving the demand for psoriasis drugs.

Download sample pages of this report: https://www.psmarketresearch.com/market-analysis/psoriasis-drugs-market-outlook/report-sample

As per the United Nations (UN), the population in the age group of 65 and above will increase from 727 million in 2020 to 1.5 billion in 2050. Since the disease is most commonly found in the age group of 50 to 70, the rise in the geriatric population would lead to an increase in the number of people suffering from it. This is because older people have a malfunctioning immune system, and since psoriasis is an autoimmune disease, they are at a high risk of it. As a result, the pipeline of psoriasis drugs under development has expanded in recent years.

Many of the drug candidates in the pipeline of pharma companies are sponsored by Pharmaceutical Research and Manufacturers of America (PhRMA). BIOCAD, Boehringer Ingelheim International GmbH, UCB S.A., Coherus BioSciences Inc., Sandoz International GmbH, Eli Lilly and Company, Pfizer Inc., Maruho Co. Ltd., MC2 Therapeutics A/S, and Dermavant Sciences Inc. are among the dermatology drug companies extensively engaged in developing medicines to manage psoriasis. In addition, many companies have received the regulatory approvals for their drugs in recent years, which is enhancing people's access to them.

The drugs being developed or launched for psoriasis are of several types, including biologic drugs, topical therapies, and small-molecule systemic drugs, among which biologics have been in the highest demand. With the increasing knowledge on the genetics and immunopathogenesis of the disease, highly effective biologics have been created, with many more under various stages of development. Many of the biologics are being designed to reduce the risk of the comorbidities of this condition, which include certain cancers.

Make inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=psoriasis-drugs-market-outlook

Currently, North America accounts for the highest consumption of drugs to treat this condition, since the awareness of people on psoriasis and the medicines available for its management is rising in the region as a result of the initiatives being taken by public and private organizations. Moreover, the region is home to the largest pharma sector in the world, which leads to the easy availability of drugs to manage this autoimmune condition.

However, Asia-Pacific (APAC) will likely be the fastest-growing psoriasis drugs market in the years to come. APAC is home to the most people on earth, which is why it has a huge potential psoriasis patient pool. Moreover, with the increasing awareness on the disease in emerging economies, pharmaceutical companies are expanding their presence here. Further, several organizations from the West are offering support for increasing the awareness and access to psoriasis drugs in the APAC region.

Hence, with more people coming to know about psoriasis, the demand for drugs that help manage it will rise.

Browse more reports:

Dermatology Drugs Market Report - https://www.psmarketresearch.com/press-release/dermatology-drugs-market

Generic Drugs Market Report - https://www.psmarketresearch.com/press-release/generic-drugs-market

Contact:
P&S Intelligence
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Blog: https://healthcarefuturetrends.blogspot.com

About P&S Intelligence

P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies.

This release was published on openPR.